Corvus Pharmaceuticals, Inc. — Form 10-Q
Filed August 6, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 5/100
What the filing says
Richard A. Miller (CEO) and Leiv Lea (CFO) certified the Form 10-Q for the quarter ended June 30, 2026, filed August 6, 2026. Both officers attest that the financial statements fairly present the company's financial condition and results of operations, and that disclosure controls and internal controls over financial reporting are effective. No material weaknesses in internal control or fraud involving management were disclosed.
Why this rating
Standard SOX 302/906 certifications with no exceptions or control deficiencies disclosed. Routine quarterly compliance filing, immaterial to business trajectory.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.